Printer Friendly

FDA PANEL RECOMMENDS APPROVAL OF 3M MULTIFOCAL INTRACCULAR LENS

 FDA PANEL RECOMMENDS APPROVAL OF 3M MULTIFOCAL INTRACCULAR LENS
 ST. PAUL, Minn., Jan. 23 /PRNewswire/ -- The Food and Drug Administration's Ophthalmic Advisory Panel today recommended approval with conditions, of the 3M (NYSE: MMM) brand Multifocal intraocular lens (IOL) for sale in the United States. The conditions are related mainly to labeling.
 The FDA relies on the clinical expertise of the advisory panels to guide its decisions. Generally, approval to market follows advisory panel recommendation.
 "The advisory panel's recommendation represents an important step forward in making this advanced lens available to ophthalmologists for treatment of cataract patients in the United States," said Robert B. Bomar, manager, 3M Vision Care. "The lens will be commercially available only after final approval by the FDA," Bomar added.
 Since 1987, the lens has been implanted in approximately 30,000 cataract patients worldwide. Of those, over 700 were involved in the U.S. study, which is currently under review by the FDA.
 An individual who undergoes cataract surgery and receives a conventional monofocal lens implant typically needs to wear eyeglasses, usually bifocals, following surgery to achieve acceptable near and far vision. The majority of patients implanted with bilateral 3M Multifocal IOLs, however, do not need to wear bifocals; and about half of these patients function entirely without the aid of eyeglasses.
 The lens has been available for sale to ophthalmologists in most countries for over two years. In March 1991, the 3M Multifocal intraocular lens was the first multifocal lens to receive commercial marketing approval from Japan's Ministry of Health and Welfare.
 -0- 01/23/92
 /CONTACT: Anne Greer, 612-736-0876, or JoAnn Klein, 612-733-7837, both of 3M/
 (MMM) CO: Minnesota Mining and Manufacturing ST: Minnesota IN: SU:


KH -- MN021 -- 2950 01/23/92 15:44 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 23, 1992
Words:290
Previous Article:U.S. DEPARTMENT OF EDUCATION OFFICIALS TO RELEASE FINAL REPORT OF THE NATIONAL COUNCIL ON EDUCATION STANDARDS AND TESTING
Next Article:BEARINGS, INC. REPORTS LOWER RESULTS FOR SECOND QUARTER AND FIRST HALF OF FISCAL YEAR; DECLARES REGULAR QUARTERLY DIVIDEND
Topics:


Related Articles
ALLERGAN REPORTS FOURTH QUARTER AND 1991 YEAR END OPERATING RESULTS FOURTH QUARTER EVENTS SUPPORT STRATEGIC DIRECTION FOR THE 1990s
UNILENS REPORTS LARGE JUMP IN MARKET SHARE, SURPASSING THE COMPETITION BY 100 PERCENT
FDA APPROVES NEW PILKINGTON BARNES HIND LENS CARE PRODUCTION FACILITY IN PHOENIX
FDA Panel Recommends Approval for AquaFlow(TM).
VISTAKON to Introduce ACUVUE(R) OASYS(TM) Brand Contact Lenses for PRESBYOPIA.
SynergEyes: the new era in hybrid contact lens technology.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters